|Articles|March 24, 2016
China-Based Biotech Selects Medidata Platform
Henlius Biotechnology has selected Medidata’s Medidata Clinical Cloud® platform for its Phase III oncology clinical trial in China.
Advertisement
China-based Shanghai Henlius Biotechnology Co. Ltd. (Henlius) has selected Medidata’s Medidata Clinical Cloud® platform, specifically Medidata Rave® (electronic data capture) and Medidata Balance® (randomization and trial supply management) in its Phase III oncology clinical trial in China.
Henlius focuses on the development, production and commercialization of monoclonal antibody drugs for a number of therapeutic areas, including oncology and auto-immune diseases.
Read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
3
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
4
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
5